Kalyan Handique

Kalyan Handique

About

Detail

Chief Innovation Officer | Serial Entrepreneur | Co-founder of Celsee & HandyLab
Ann Arbor, Michigan, United States

Timeline

work
Job
school
Education
auto_stories
Publication

Résumé

Jobs verified_user 0% verified
  • BioRad Laboratories
    Chief Innovation Officer, CDG
    BioRad Laboratories
    Apr 2023 - Jan 2026 (2 years 10 months)
  • BioRad Laboratories
    VP, CDG Advanced Technology
    BioRad Laboratories
    Feb 2021 - Apr 2023 (2 years 3 months)
  • C
    President
    Celsee Inc
    Nov 2017 - Apr 2020 (2 years 6 months)
  • P
    Board Director
    PHASIQ Inc
    Jan 2015 - Dec 2016 (2 years)
  • Augment Ventures
    Advisor
    Augment Ventures
    Aug 2011 - Dec 2023 (12 years 5 months)
  • C
    President & CEO
    Celsee Diagnostics Inc DeNovo Sciences
    Aug 2011 - Nov 2017 (6 years 4 months)
  • D
    Board Director
    D Biomatrix
    Jan 2011 - Dec 2016 (6 years)
  • Z
    Advisor
    Zell Lurie Commercialization Fund
    Jan 2010 - Dec 2025 (16 years)
  • C
    Strategic Industrial Advisor
    Center for Wireless Integrated MicroSensing and Systems University of Michigan
    Jan 2010 - Dec 2014 (5 years)
  • BD
    Vice President, R & D Systems Development, BD Infectious Disease
    BD
    Nov 2009 - Jul 2011 (1 year 9 months)
  • H
    Co-founder & CTO
    HandyLab Inc
    Jan 2000 - Nov 2009 (9 years 11 months)
Education verified_user 0% verified
  • University of Michigan
    Ph.D, Chemical Engineering
    University of Michigan
    Jan 1995 - Dec 2000 (6 years)
  • Indian Institute of Technology Bombay
    B.Tech, Chemical Engineering
    Indian Institute of Technology Bombay
    Jan 1991 - Dec 1995 (5 years)
  • K
    Kendriya Vidyalaya, Khanapara, Assam, India
    Kendriya Vidyalaya Khanapara Assam India
    Jan 1979 - Dec 1990 (12 years)
Publications verified_user 0% verified
  • i
    a novel microchannel-based device to capture and analyze circulating tumor cells (ctcs) of breast cancer.
    international journal of oncology
    Mar 2014
    circulating tumor cells (ctcs) have been shown in many studies as a possible biomarker for metastasis and may be instrumental for the spread of the disease. despite advances in ctc capturing technologies, the low frequency of ctcs in cancer patients and the heterogeneity of the ctcs have limited the wide application of the technology in clinic. in this study, we investigated a novel microfluidic technology that uses a size- and deformability-based capture system to characterize ctcs. this unique platform not only allows flexibility in the selection of antibody markers but also segregates the ctcs in their own chambers, thus, enabling morphological, immunological and genetic characterization of each ctc at the single cell level. in this stud
This is a community-created genome.